Is Trump the Only One Bold Enough To Call Out Israel and Iran?


In this issue:
- China is still getting restricted U.S. chips for its defense
- Trump called a ceasefire between Israel and Iran, but it quickly collapsed
- Hims & Hers' stock crushes after losing a major deal
Let’s break it down.
Is China Using Forbidden U.S. Chips For the Army?
Briefing: Chinese AI company DeepSeek, based in a sub-provincial city in East China, Hangzhou, is being accused of helping China's military and intelligence by U.S officials. The company is ducking U.S. export controls meant to block access to powerful American-made chips.
Details: DeepSeek promotes its AI models as affordable and top-level, but U.S. officials say the company has ties to China’s military and shows up in over 150 Chinese military procurement documents. DeepSeek reportedly operated secretly and exported chips using a fake firm in Southeast Asia and rented time on foreign servers where the chips are already installed and tapped into their power from afar. Nvidia says it only sold China the H800 chip, which is legal for export, and not the more advanced H100 chip. DeepSeek is also accused of sharing user information to the Chinese government through China Mobile, which is one of the biggest phone and internet companies in China. For now, DeepSeek hasn’t been punished or blocked by the U.S., but investigations are ongoing.
Why It Matters: This brings to attention how AI and advanced chips are at the center of the tech rivalry between the U.S. and China. It also raises questions about how export bans can be enforced, including data privacy, national security, and how tech is being used in modern military operations.
Is Trump the Only One Bold Enough To Call Out Israel and Iran?
Briefing: Trump criticized both Israel and Iran after a ceasefire he announced on June 24 fell apart within hours. While heading to a NATO (North Atlantic Treaty Organization) Summit, he urged both countries to stop fighting, but soon after, rockets and airstrikes resumed.
Details: Iran launched rockets at Israel, and Israel retaliated by targeting Iranian sites, including a radar facility near Tehran. Frustrated that the ceasefire broke down so quickly, Trump reportedly said both countries had “no idea what the f*** they’re doing” and urged Israel to stop its attacks. He told Israeli pilots to hold their fire and go back home. After Trump spoke to Prime Minister Benjamin Netanyahu, the Israeli officials said they paused more attacks.
Why It Matters: The ceasefire collapsing shows how difficult it is to keep peace between Israel and Iran. It also shows that Trump is still trying to play a big role in major world events, reminding us how shaky peace efforts in the region are and how quickly they can fall apart.
Did Novo Just Back Out of a Deal with Hims & Hers to Kill the Competition?
Briefing: Hims & Hers just lost a big business deal, and its stock dropped, around 33% of its value. The company had a deal was with Novo Nordisk, which makes a well-known weight-loss medicine called WeGovy.
Details: The plan was to offer Wegovy through the Hims & Hers website and app, similar to a virtual doctor visit. But Novo Nordisk suddenly pulled out of the deal because Hims & Hers was still selling cheaper versions of the same medicine from special pharmacies that mix drugs, called compounders. Novo Nordisk called that risky and misleading for customers.
Novo also pointed out that since WeGovy is no longer in short supply, FDA rules don’t allow compounded versions to be sold. Hims & Hers disagreed. Its CEO said they were just trying to make the medicine more affordable, and claimed Novo didn’t want to deal with competition.
Why It Matters: This is important because it shows a power struggle between big drug companies and online health platforms over who controls access to medicine. It also shows how quickly health rules can shift, especially when it comes to in-demand medicine like WeGovy. Now, other telehealth companies may need to be more attentive about how they handle and offer certain medications and the way they follow FDA rules.
*Disclaimer: The content in this newsletter is for informational purposes only. We do not provide medical, legal, investment, or professional advice. While we do our best to ensure accuracy, some details may evolve over time or be based on third-party sources. Always do your own research and consult professionals before making decisions based on what you read here.